375 results about "Neurologic function" patented technology

The present invention is a fully automated computer controlled system for adjustment of neurostimulation implants used in pain therapy and in treating neurological dysfunction which includes a patient interactive computer, and a universal transmitter interface integrally embedded in the patient interactive computer, or built into the antenna which is capable of stimulating any type of implanted neurostimulation devices by imitating any of the proprietary programming codes. The patient interacts with the system through the patient interactive computer (containing a unique software) which provides for consistency check of the data entered by the patient, deleting the entered data if the consistency check was not satisfactory, and requesting the patient to re-enter the data.

Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.

The present invention relates to a method and apparatus for monitoring haemodynamic function in animals and humans during anaesthesia and surgery. During anaesthesia and surgery the subject's haemodynamic, respiratory, neuromuscular and neurological functions are monitored as indicators of the condition of the health of the subject. Commonly, variations in blood pressure are used to imply corresponding variations in cardiac output, i.e. good blood pressure equals good cardiac output. The present invention utilizes a device to monitor changes of blood flow in peripheral blood vessels of the subject as an indicator of cardiac output. This is believed to provide a much more accurate indicator.

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and / or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and / or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and / or a cognitive retraining program, and / or a dietary program designed to maximize insulin and glucose metabolism.

The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

Therapeutic methods for enhancing neurologic function such as may be desired in individuals having motor and / or cognitive impairment, including that resulting from Alzheimer's disease, dementia, head trauma, mental disease such as depression, stroke and neurodegeneration, as well as in healthy individuals are described, the methods including delivering a cognitive enhancing effective amount of light energy having a wavelength in the visible to near-infrared wavelength range to a target area of the brain. The neurologic function enhancing effective amount of light energy, in accordance with a preferred embodiment, is a predetermined power density (mW / cm2) at the level of the brain tissue being treated, and is delivered by determining a surface power density of the light energy that is sufficient to deliver the predetermined power density of light energy to the target brain tissue. In one embodiment, progenitor cells are treated using light energy and implanted into the central nervous system of a patient.

A method and a device for non-invasive blood pressure measurement wherein the angle between the hand and the wrist, and the turning angle of the wrist relative to the middle part of the forearm, are kept to the most suitable degree for measuring the blood pressure of the radial artery. At least one pressure bladder and one arterial pulse transducer array are placed on the skin over the radial artery of the wrist to apply the external pressure to the artery and to detect the change of the arterial pulse signals. This method and device can correctly measure the intermittent or continuous blood pressure of the radial artery or the ulnar artery based on the principles of oscillation method and volume compensation method, and effectively eliminate the influence on the measurement due to body movement and the influence on blood circulation and neural function of the hand caused by long-term blood pressure measurement.

A method of presenting multiple image sources of approximately registered images so that the mind can easily fuse the multiple images into one image. Improvement to fusing can be achieved by alternating views between sources at 85 hertz or more. The insertion of a black frame between the succession of frames optimizes the neurological functions of the human optical system (produces retinal decay) such that the perception of a useful fused image is greatly enhanced. Stereographic fusion can also be achieved to allow for fusion of loosely registered datasets.

The invention discloses a heart rate variability analyzing method based on an amplitude spectrum and instruments. The method comprises the following steps that a human body autonomic nervous function monitor is installed, after amplification, filtering and analog-digital conversion are carried out on electrocardio signals collected by an electrocardio electrode slice, an RR interval time sequence is built, the QRS waveform of the electrocardio signals has the features of large amplitude, short time limit, steep waveform and easy recognition, the key for obtaining HRV signals is that the R wave of an electrocardiogram is accurately calibrated, and according to the morphological characteristic of an R wave picture, the wave crest of the R wave is the maximum positive value in a single signal period; the instruments included in the method comprise a preamplifier module used for amplifying the electrocardio signals, a filter module, an A / D conversion module, an R crest positioning module, a signal pseudo crest pseudo differential eliminating module, an RR sequence forming module, an interpolation module and a display module which are sequentially connected, the preamplifier module is connected with the electrocardio electrode slice through a guide line, and the electrode slice is arranged on the surface of the human body skin and used for collecting the electrocardio signals of the human body.

Disclosed is a method for interacting with the nervous system. The method includes detecting signals associated with a biological function at one or more sensors. It also includes processing the signals to create a representation thereof, delivering effector responses based on the representations, and controlling a physical process.

A method for treating a subject having Parkinson's disease or Alzheimer's disease is provided. The method includes noninvasively delivering light energy having a wavelength of about 630 nanometers to about 904 nanometers to the brain of the subject. Delivering the light energy includes (i) irradiating the scalp with light energy having an incident power density between about 10 mW / cm2 to about 10 W / cm2, (ii) transmitting a portion of the light energy through the scalp and the skull to the brain, wherein the transmitted light energy has a power density of at least about 0.01 mW / cm2 at a depth of approximately 2 centimeters below the dura, or both (i) and (ii).

The invention discloses a GRPAK / tetrahydroglyoxaline / RGD ternary conjugate as well as a preparation method and application of the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate. According to the preparation method, L-Lys is served as a link arm, and 1, 3-dioxo-2-[(4-peracetic acid) phenyl]-4, 4, 5, 5-tetramethyl tetrahydroglyoxaline, the GRPAK pentapeptide with a thrombolytic effect, and RGD tetrapeptide with an antithrombosis effect are integrally linked, thus obtaining the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate as shown in formula I. The GRPAK / tetrahydroglyoxaline / RGD ternary conjugate disclosed by the invention has high activity on removing NO free radical, excellent thrombolytic activity and antithrombosis activity; as in-vivo apoplexy activity shown, the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate can effectively protect the neurologic function of a rat subjected to apoplexy, and reduces the brain infarct volume of the rat subjected to apoplexy, and has high apoplexy resisting activity, and can be prepared into a clinical medicine for treating apoplexy or cerebral infarction.

The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease.

Systems and methods for monitoring phrenic nerve function of a patient are disclosed, including, including establishing a diaphragmatic movement value threshold; positioning a diaphragmatic movement sensor on an external surface of an abdomen of the patient; applying a treatment regimen to a tissue region in proximity to the phrenic nerve; measuring a diaphragmatic movement value with the diaphragmatic movement sensor; comparing the measured diaphragmatic movement value to the established diaphragmatic movement value threshold; and generating an alert in response to the comparison.

The present invention discloses method and apparatus of detecting, exciting and regenerating sensation, motor and internal organ signals of vertebrate including human, and is especially one kind microelectronic system aided nerve channel function recovering method and apparatus. The nerve channel function recovering apparatus includes two parts, one part for the function reconstruction of the ascending nerve channel and the other part for the function reconstruction of the descending nerve channel. The weak electric signal of the damaged nerve tract or nerve fiber is detected with detecting electrodes, amplified, recognized and extracted to generate controlled electric exciting signal for exciting the damaged nerve tract or nerve fiber to regenerate corresponding nerve signal and restore the function of the damaged nerve tract or nerve fiber micro electronically.

The invention provides methods and kits for detecting, screening, quantifying or localizing the etiology for reduced or impaired cranial nerve function or conduction or associated cranial nucleus or supranuclear input, useful for detecting, diagnosing or screening for increased intracranial pressure, or useful for detecting, diagnosing, monitoring progression of or screening for a disease or condition featuring increased intracranial pressure by tracking eye movement of the subject. The methods may be performed by a) analyzing eye movement of the subject; b) comparing eye movement of the subject to eye movement of a control or the subject's own baseline eye movement; and c) identifying the subject as having eye movement significantly different from the control or the subject's own baseline eye movement.

The invention discloses an exercise instrument for preventing deep venous thrombosis of lower limbs. The exercise instrument for preventing deep venous thrombosis of lower limbs comprises a casing, the upper end of the casing is provided with two sliding grooves with corresponding positions, a measuring side wall of the casing is respectively provided with a first device chamber and a sliding plugchamber, the side wall of the casing is fixedly connected to a driving motor, one end of an output shaft of the driving motor located in the first device chamber is fixedly connected to a first bevelgear, the inner wall of the first device chamber is rotatably connected to a driving wheel, the side wall of the driving wheel is coaxially fixedly connected to a second bevel gear meshed with the first bevel gear, the upper end of the casing is provided with a first groove communicated with the first device chamber, and the inner walls of the two sliding grooves are rotatably connected to parallelly-arranged first reciprocating lead screws. The exercise instrument for preventing deep venous thrombosis of lower limbs can massage the foot sole and instep to achieve a function of stimulating limb nerves, an ankle joint is protected from stiffness deformation, the foot drop is effectively prevented, and the rehabilitation of a patient is promoted.

It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

The invention discloses a hand automatic rehabilitation training system and training method of a hemiplegic patient. The hand automatic rehabilitation training system comprises a double-core embeddedmicroprocessor module, a front arm muscle body module, a surface electromyogram signal acquiring module, an electromyogram decoding module, a wireless communication module, a power source management module, a detection module, a rehabilitation glove module, a driving module which is used for driving a motor on each finger to work, a neural prosthesis module and an upper computer module. A driving-driven control strategy is adopted by the training method, and a wearable glove system and a human body control system can be linked to reshape motor nerves; a monotonous stimulation mode is changed,muscle fatigue is avoided, and the nervous function is rebuilt; by conducting blind source separation on a surface electromyogram signal, the decoding precision is improved, so that rehabilitation training pays more attention to improving the ADL capacity. The hand automatic rehabilitation training system and training method of the hemiplegic patient have the obvious advantages of being intelligent, high in practicability, convenient to use and the like; the patient can automatically conduct hand rehabilitation training at home, and the application value is high.

Systems and methods for monitoring phrenic nerve function of a patient are disclosed, including, including establishing a diaphragmatic movement value threshold; positioning a diaphragmatic movement sensor on an external surface of an abdomen of the patient; applying a treatment regimen to a tissue region in proximity to the phrenic nerve; measuring a diaphragmatic movement value with the diaphragmatic movement sensor; comparing the measured diaphragmatic movement value to the established diaphragmatic movement value threshold; and generating an alert in response to the comparison.

The present invention provides a quinolone compound represented by General Formula (1)or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

The invention relates to the use of human lysozyme in pharmaceutical industry, in particular the use in preparing medicines for treating dermatosis, infection and ulceration caused by bacteria, fungus, viruses, allergic reaction, and occupational diseases, physical diseases, nerve dysfunctional diseases, and immunity diseases. The invention exploits the novel use of human lysozyme in medical treatment, the gene recombination lysozyme has rich source, the invention also features simple process for manufacturing, and ease in use.

The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and / or neurological dysfunction and / or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.

The invention discloses an evaluation system and method based on neurological function rehabilitation active training, and belongs to the technical field of rehabilitation training. In the system, a qualitative evaluation module classifies and identifies limb actions acquired by a limb action acquisition module based on a limb action processing module, and compares the limb actions with a Brunnstrom scale to obtain a Brunnstrom staging result; a myoelectricity evaluation module is used for carrying out myoelectricity evaluation on a muscle capability diagram obtained by processing myoelectricity signals acquired by a myoelectricity signal acquisition module based on a myoelectricity data processing module; an electroencephalogram evaluation module is used for carrying out brain region evaluation on a brain topographic map and a brain region energy conversion map which are obtained by processing electroencephalogram signals acquired by an electroencephalogram signal acquisition module based on an electroencephalogram data processing module; and a rehabilitation evaluation module combines the Brunnstrom staging result, the myoelectricity evaluation result and the brain region evaluation result for rehabilitation evaluation to obtain a rehabilitation evaluation report. According to the method, the rehabilitation state of the patient can be evaluated accurately and scientifically through the evaluation method of multi-information fusion of electroencephalogram, myoelectricity and postures.

A system includes a guidance device that provides feedback to a user to compress a patient's chest at a rate of between about 90 and 110 compressions per minute and at a depth of between about 4.5 centimeters to about 6 centimeters. The system includes a pressure regulation system having a pressure-responsive valve that is configured to be coupled to a patient's airway. The pressure-responsive valve is configured to remain closed during successive chest compressions in order to permit removal at least about 200 ml from the lungs in order to lower intracranial pressure to improve survival with favorable neurological function. The pressure-responsive valve is configured to remain closed until the negative pressure within the patient's airway reaches about −7 cm H2O, at which time the pressure-responsive valve is configured to open to provide respiratory gases to flow to the lungs through the pressure-responsive valve.

The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.

The invention belongs to the field of biological medicine, and particularly relates to a Nogo-A receptor binding peptide as well as a derivative and an application thereof. The amino acid residue sequence of the Nogo-A receptor binding peptide is HIYTALV or GFATITG. The derivative of the binding peptide is a product obtained through conventional modification of an amino terminal or a carboxyl terminal of a Nogo-A receptor binding peptide fragment on a Nogo-A receptor binding peptide amino acid side chain group or a product obtained by connecting a label used for peptide or protein detection or purification on the Nogo-A receptor binding peptide. The binding peptide and the derivative of the binding peptide can be bound with NgR in vitro, nerve regeneration is promoted by preventing binding of NgR and Nogo-A, nerve regeneration barriers caused by central nervous injury diseases can be treated, recovery of a central nervous function is promoted, and the binding peptide and the derivative can be widely applied in the medical and biological fields.

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.